| Proliferation marker Ki-67 in early breast cancer A Urruticoechea, IE Smith, M Dowsett Journal of clinical oncology 23 (28), 7212-7220, 2005 | 1127 | 2005 |
| Recent advances in cancer therapy: an overview A Urruticoechea, R Alemany, J Balart, A Villanueva, F Vinals, G Capella Current pharmaceutical design 16 (1), 3-10, 2010 | 594 | 2010 |
| RANK induces epithelial–mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis M Palafox, I Ferrer, P Pellegrini, S Vila, S Hernandez-Ortega, ... Cancer research 72 (11), 2879-2888, 2012 | 220 | 2012 |
| Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy C Saura, J Bendell, G Jerusalem, S Su, Q Ru, S De Buck, D Mills, ... Clinical Cancer Research 20 (7), 1935-1945, 2014 | 140 | 2014 |
| Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer CA Maxwell, J Benítez, L Gómez-Baldó, A Osorio, N Bonifaci, ... PLoS biology 9 (11), e1001199, 2011 | 134 | 2011 |
| Molecular response to aromatase inhibitor treatment in primary breast cancer A Mackay, A Urruticoechea, JM Dixon, T Dexter, K Fenwick, A Ashworth, ... Breast Cancer Research 9, 1-14, 2007 | 134 | 2007 |
| Treatment of malignant superior vena cava syndrome by endovascular stent insertion: experience on 52 patients with lung cancer A Urruticoechea, R Mesıa, J Domınguez, C Falo, E Escalante, A Montes, ... Lung Cancer 43 (2), 209-214, 2004 | 131 | 2004 |
| Novel inhibitors of fatty acid synthase with anticancer activity T Puig, C Turrado, B Benhamú, H Aguilar, J Relat, S Ortega-Gutiérrez, ... Clinical Cancer Research 15 (24), 7608-7615, 2009 | 130 | 2009 |
| A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines T Puig, H Aguilar, S Cufí, G Oliveras, C Turrado, S Ortega-Gutiérrez, ... Breast Cancer Research 13, 1-13, 2011 | 124 | 2011 |
| Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast … A Urruticoechea, M Rizwanullah, SA Im, ACS Ruiz, I Láng, G Tomasello, ... Journal of Clinical Oncology 35 (26), 3030-3038, 2017 | 117 | 2017 |
| Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment J Amézaga, B Alfaro, Y Ríos, A Larraioz, G Ugartemendia, ... Supportive Care in Cancer 26, 4077-4086, 2018 | 106 | 2018 |
| Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence S Pernas, M Gil, A Benítez, MT Bajen, F Climent, MJ Pla, E Benito, ... Annals of surgical oncology 17, 772-777, 2010 | 96 | 2010 |
| Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC) A Urruticoechea, M Arnedos, G Walsh, M Dowsett, IE Smith Breast cancer research and treatment 110, 411-416, 2008 | 94 | 2008 |
| Biological reprogramming in acquired resistance to endocrine therapy of breast cancer H Aguilar, X Solé, N Bonifaci, J Serra-Musach, A Islam, N Lopez-Bigas, ... Oncogene 29 (45), 6071-6083, 2010 | 83 | 2010 |
| Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population J Gómez-Miragaya, M Palafox, L Paré, G Yoldi, I Ferrer, S Vila, P Galván, ... Stem cell reports 8 (5), 1392-1407, 2017 | 78 | 2017 |
| Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors N Travier, A Fonseca-Nunes, C Javierre, E Guillamo, L Arribas, I Peiro, ... Medical oncology 31, 1-11, 2014 | 77 | 2014 |
| Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to … S Cufí, A Vazquez-Martin, C Oliveras-Ferraros, B Corominas-Faja, ... Oncotarget 3 (12), 1600, 2012 | 76 | 2012 |
| Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin) B Martin-Castillo, C Oliveras-Ferraros, A Vazquez-Martin, S Cufí, ... Cell Cycle 12 (2), 225-245, 2013 | 66 | 2013 |
| Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy B Pistilli, T Pluard, A Urruticoechea, D Farci, A Kong, T Bachelot, S Chan, ... Breast cancer research and treatment 168, 357-364, 2018 | 56 | 2018 |
| Altered red blood cell membrane fatty acid profile in cancer patients J Amézaga, S Arranz, A Urruticoechea, G Ugartemendia, A Larraioz, ... Nutrients 10 (12), 1853, 2018 | 55 | 2018 |
